These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. The PARP inhibitor AZD2281 (Olaparib) induces autophagy/mitophagy in BRCA1 and BRCA2 mutant breast cancer cells. Arun B; Akar U; Gutierrez-Barrera AM; Hortobagyi GN; Ozpolat B Int J Oncol; 2015 Jul; 47(1):262-8. PubMed ID: 25975349 [TBL] [Abstract][Full Text] [Related]
4. Mutation landscape of germline and somatic BRCA1/2 in patients with high-grade serous ovarian cancer. Eoh KJ; Kim HM; Lee JY; Kim S; Kim SW; Kim YT; Nam EJ BMC Cancer; 2020 Mar; 20(1):204. PubMed ID: 32164585 [TBL] [Abstract][Full Text] [Related]
5. Olaparib Use in Patients With Metastatic Breast Cancer Harboring Somatic BRCA1/2 Mutations or Mutations in Non-BRCA1/2, DNA Damage Repair Genes. Walsh EM; Mangini N; Fetting J; Armstrong D; Chan IS; Connolly RM; Fiallos K; Lehman J; Nunes R; Petry D; Reynolds J; Shah M; Smith KL; Visvanathan K; Lauring J; Park BH; Stearns V; Wolff AC Clin Breast Cancer; 2022 Jun; 22(4):319-325. PubMed ID: 35074264 [TBL] [Abstract][Full Text] [Related]
6. The PARP1 selective inhibitor saruparib (AZD5305) elicits potent and durable antitumor activity in patient-derived BRCA1/2-associated cancer models. Herencia-Ropero A; Llop-Guevara A; Staniszewska AD; Domènech-Vivó J; García-Galea E; Moles-Fernández A; Pedretti F; Domènech H; Rodríguez O; Guzmán M; Arenas EJ; Verdaguer H; Calero-Nieto FJ; Talbot S; Tobalina L; Leo E; Lau A; Nuciforo P; Dienstmann R; Macarulla T; Arribas J; Díez O; Gutiérrez-Enríquez S; Forment JV; O'Connor MJ; Albertella M; Balmaña J; Serra V Genome Med; 2024 Aug; 16(1):107. PubMed ID: 39187844 [TBL] [Abstract][Full Text] [Related]
7. Lin KK; Harrell MI; Oza AM; Oaknin A; Ray-Coquard I; Tinker AV; Helman E; Radke MR; Say C; Vo LT; Mann E; Isaacson JD; Maloney L; O'Malley DM; Chambers SK; Kaufmann SH; Scott CL; Konecny GE; Coleman RL; Sun JX; Giordano H; Brenton JD; Harding TC; McNeish IA; Swisher EM Cancer Discov; 2019 Feb; 9(2):210-219. PubMed ID: 30425037 [TBL] [Abstract][Full Text] [Related]
8. Response to olaparib in metastatic castration-resistant prostate cancer with germline BRCA2 mutation: a case report. Ma Y; He L; Huang Q; Zheng S; Zhang Z; Li H; Liu S BMC Med Genet; 2018 Oct; 19(1):185. PubMed ID: 30333000 [TBL] [Abstract][Full Text] [Related]
9. BRCA2 Reversion Mutation Associated With Acquired Resistance to Olaparib in Estrogen Receptor-positive Breast Cancer Detected by Genomic Profiling of Tissue and Liquid Biopsy. Gornstein EL; Sandefur S; Chung JH; Gay LM; Holmes O; Erlich RL; Soman S; Martin LK; Rose AV; Stephens PJ; Ross JS; Miller VA; Ali SM; Blau S Clin Breast Cancer; 2018 Apr; 18(2):184-188. PubMed ID: 29325860 [No Abstract] [Full Text] [Related]
10. Olaparib for the treatment of breast cancer. Robert M; Frenel JS; Gourmelon C; Patsouris A; Augereau P; Campone M Expert Opin Investig Drugs; 2017 Jun; 26(6):751-759. PubMed ID: 28395540 [TBL] [Abstract][Full Text] [Related]
11. Routine Plasma-Based Genotyping to Comprehensively Detect Germline, Somatic, and Reversion Vidula N; Rich TA; Sartor O; Yen J; Hardin A; Nance T; Lilly MB; Nezami MA; Patel SP; Carneiro BA; Fan AC; Brufsky AM; Parker BA; Bridges BB; Agarwal N; Maughan BL; Raymond VM; Fairclough SR; Lanman RB; Bardia A; Cristofanilli M Clin Cancer Res; 2020 Jun; 26(11):2546-2555. PubMed ID: 32034076 [TBL] [Abstract][Full Text] [Related]
12. TBCRC 048: Phase II Study of Olaparib for Metastatic Breast Cancer and Mutations in Homologous Recombination-Related Genes. Tung NM; Robson ME; Ventz S; Santa-Maria CA; Nanda R; Marcom PK; Shah PD; Ballinger TJ; Yang ES; Vinayak S; Melisko M; Brufsky A; DeMeo M; Jenkins C; Domchek S; D'Andrea A; Lin NU; Hughes ME; Carey LA; Wagle N; Wulf GM; Krop IE; Wolff AC; Winer EP; Garber JE J Clin Oncol; 2020 Dec; 38(36):4274-4282. PubMed ID: 33119476 [TBL] [Abstract][Full Text] [Related]
13. PARP inhibitor resistance and TP53 mutations in patients treated with olaparib for BRCA-mutated cancer: Four case reports. Collot T; Niogret J; Carnet M; Chevrier S; Humblin E; Favier L; Bengrine-Lefevre L; Desmoulins I; Arnould L; Boidot R Mol Med Rep; 2021 Jan; 23(1):. PubMed ID: 33236159 [TBL] [Abstract][Full Text] [Related]
14. HRDetect is a predictor of BRCA1 and BRCA2 deficiency based on mutational signatures. Davies H; Glodzik D; Morganella S; Yates LR; Staaf J; Zou X; Ramakrishna M; Martin S; Boyault S; Sieuwerts AM; Simpson PT; King TA; Raine K; Eyfjord JE; Kong G; Borg Å; Birney E; Stunnenberg HG; van de Vijver MJ; Børresen-Dale AL; Martens JW; Span PN; Lakhani SR; Vincent-Salomon A; Sotiriou C; Tutt A; Thompson AM; Van Laere S; Richardson AL; Viari A; Campbell PJ; Stratton MR; Nik-Zainal S Nat Med; 2017 Apr; 23(4):517-525. PubMed ID: 28288110 [TBL] [Abstract][Full Text] [Related]
15. Resurrection of PARP Inhibitors in Breast Cancer. Lyons TG; Robson ME J Natl Compr Canc Netw; 2018 Sep; 16(9):1150-1156. PubMed ID: 30181424 [TBL] [Abstract][Full Text] [Related]
16. Reversion and non-reversion mechanisms of resistance to PARP inhibitor or platinum chemotherapy in BRCA1/2-mutant metastatic breast cancer. Waks AG; Cohen O; Kochupurakkal B; Kim D; Dunn CE; Buendia Buendia J; Wander S; Helvie K; Lloyd MR; Marini L; Hughes ME; Freeman SS; Ivy SP; Geradts J; Isakoff S; LoRusso P; Adalsteinsson VA; Tolaney SM; Matulonis U; Krop IE; D'Andrea AD; Winer EP; Lin NU; Shapiro GI; Wagle N Ann Oncol; 2020 May; 31(5):590-598. PubMed ID: 32245699 [TBL] [Abstract][Full Text] [Related]
18. Olaparib for the treatment of breast cancer. Griguolo G; Dieci MV; Guarneri V; Conte P Expert Rev Anticancer Ther; 2018 Jun; 18(6):519-530. PubMed ID: 29582690 [TBL] [Abstract][Full Text] [Related]
19. Prevalence of BRCA1, BRCA2, and PALB2 genomic alterations among 924 Taiwanese breast cancer assays with tumor-only targeted sequencing: extended data analysis from the VGH-TAYLOR study. Cheng HF; Tsai YF; Liu CY; Hsu CY; Lien PJ; Lin YS; Chao TC; Lai JI; Feng CJ; Chen YJ; Chen BF; Chiu JH; Tseng LM; Huang CC Breast Cancer Res; 2023 Dec; 25(1):152. PubMed ID: 38098088 [TBL] [Abstract][Full Text] [Related]
20. Homologous Recombination Defects and Mutations in DNA Damage Response (DDR) Genes Besides Voutsadakis IA; Stravodimou A Anticancer Res; 2023 Mar; 43(3):967-981. PubMed ID: 36854505 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]